Publications by authors named "M Tsugawa"
Article Synopsis
- This study evaluated the long-term impacts of tofogliflozin, an SGLT2 inhibitor, on atherosclerosis and key health markers in type 2 diabetes patients without cardiovascular disease.
- Over a 2-year period, both tofogliflozin and conventional treatments reduced carotid intima-media thickness, but with no notable difference between the two groups.
- Tofogliflozin showed advantages in improving blood sugar, cholesterol, BMI, waist circumference, and blood pressure compared to conventional treatment, while safety metrics were not significantly different between groups.
Article Synopsis
- The report discusses a multicenter, randomized controlled trial aimed at determining if targeted antimicrobial prophylaxis, based on rectal culture screening, can prevent acute bacterial prostatitis after transrectal prostate biopsy (TRPB).
- Patients in the trial will be split into two groups: one receiving tailored antibiotics like tazobactam-piperacillin or levofloxacin, and the other receiving standard levofloxacin treatment.
- The study's main goal is to measure the rate of acute bacterial prostatitis occurrences post-biopsy, with recruitment for the trial starting in April 2021 and a target of 5,100 participants.
Introduction: Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM).
Methods: This is the prespecified subanalysis study of the "Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)" trial.
Background: Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP). This study evaluated the effects of tofogliflozin on the brachial-ankle pulse wave velocity (baPWV) in patients with type 2 diabetes (T2DM) without a history of apparent cardiovascular disease.
Methods: The using tofogliflozin for possible better intervention against atherosclerosis for type 2 diabetes patients (UTOPIA) trial is a prospective, randomized, open-label, multicenter, parallel-group, comparative study.
Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT).
Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofogliflozin treatment group (n = 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n = 171).